Valemetostat tosylate not checked
Daiichi Sankyo · DS-3201b · DS-3201
FollowEvery change as it happens, and a Monday email
Trials
7 active
10 in total · 6 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity”In the company’s words, NCT04703192 on ClinicalTrials.gov
- Tested for
- Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma, Non-small Cell Lung Cancer, Lung Cancer, Lymphoma, Malignant, Non-hodgkin Lymphoma, Metastatic Castration-resistant Prostate Cancer, Advanced Solid Tumor
- Main trialPhase 2
- “This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.”In the company’s words, NCT04703192 on ClinicalTrials.gov
- Other names
- DS-3201b · Valemetostat · DS-3201
Other drugs for Relapsed/Refractory Peripheral T-Cell Lymphoma
- XNW5004Evopoint Biosciences Inc. · Phase 3
- GolidocitinibDizal Pharmaceuticals · Phase 3
- SoquelitinibCorvus Pharmaceuticals, Inc. · Phase 3
- Liposomal mitoxantrone hydrochlorideCSPC · Phase 3
- DuvelisibSecuraBio · Phase 3
- BelinostatAcrotech Biopharma Inc. · Phase 3
Coming up3
- 31 Jan 2028Phase 1 trial completes · ClinicalTrials.gov
- 30 Mar 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 1 Nov 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 10 May 2023 | Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) | |
| Phase 1/2Active, not recruiting | 30 Mar 2028 | A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | |
| Phase 1Active, not recruiting | 31 Dec 2022 | DS-3201b in Participants With Lymphomas | |
| Phase 1Recruiting | 31 Jan 2028 | A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) | |
| Phase 1Active, not recruiting | 1 Nov 2028 | A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors | |
| Phase 2Completed | 24 Apr 2021 | Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma | |
| Phase 1Completed | 23 Feb 2021 | Study of Single-dose DS-3201b in Participants With Hepatic Impairment | |
| Phase 1Terminated | 9 Mar 2021 | DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL) | |
| Phase 2Authorised | not given | VALYM - A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma | |
| Phase 2Authorised | not given | An open label phase II platform modular study exploring the efficacy and safety of the Valemetostat (EZH1/2 inhibitor) in patients with selected solid tumors (EZHiSWITCH) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026